Overview

Gastrointestinal Dysmotility on Aspiration Risk

Status:
Not yet recruiting
Trial end date:
2027-07-18
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that esophageal and gastric dysmotility increase the risk of developing aspiration-associated symptoms in children with neurologic impairment. The investigators are conducting a ten week cross over study comparing prucalopride to famotidine for the treatment of aspiration-associated symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Children's Hospital
Treatments:
Famotidine
Prucalopride